Astrazeneca plc recently provided details on the discovery of the potent, direct and selective NLPR3 inflammasome inhibitor AZD-4144 for the treatment of inflammatory diseases; the drug is currently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results